FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324862852> ?p ?o ?g. }

• W2324862852 endingPage "614" @default.
• W2324862852 startingPage "613.2" @default.
• W2324862852 abstract "<h3>Background</h3> Concurrent use of methotrexate (MTX) and a biologic is generally the standard-of-care in patients with RA who have disease activity despite MTX. It has been estimated that between 10 and 30% of RA patients are MTX-intolerant (1). For patients who are prescribed treatment with a biologic agent and not tolerating MTX, biological monotherapy may be considered. From DANBIO it has been estimated that 19% of RA patients in Denmark are in biologic monotherapy (2). <h3>Objectives</h3> To elucidate the effectiveness (CDAI remission rates) and drug adherence of bDMARD therapies prescribed as monotherapy in Danish RA patients. <h3>Methods</h3> All RA patients, treated with bDMARDs registered in DANBIO as initiating bDMARD as monotherapy, i.e. without concomitant conventional synthetic DMARDs (csDMARDs), from May 1 2011 to April 30 2013, were eligible for inclusion (2). Descriptive statistics for effectiveness and drug adherence of bDMARD monotherapy were calculated. <h3>Results</h3> 775 patients were included (77% women, disease duration (mean [SD]): 12.6 [10.8], age: 56.0 years [12.9], 71% IgM-RF positive, CDAI: 21.1 [14.5], and DAS28: 4.4 [1.6]. At 6 months follow-up CDAI remission rates were principally separated into two clusters; a group with “poor” (0-10%) remission rates (consisting of abatacept [0/11], certolizumab [1/10] and infliximab [2/32]), and a group with “good” (above 20%) remission rates (adalimumab [35/124], etanercept [46/215], golimumab [4/16] and tocilizumab [23/86]), with rituximab in between [15%; 10/69]) (Figure). Overall, DAS28 remission was achieved in 41% (242/587), with similar pattern of remission between drugs as CDAI remission rates. With the exception of patients treated with infliximab (14%) and rituximab (16%), around one third of the patients achieved an ACR50 response (105/339). After 2 years of monotherapy, the proportion of patients still on drug was more than two thirds, when excluding infliximab. As illustrated in the figure the drug adherence rate was apparently highest for etanercept and adalimumab, and in a post hoc analysis, infliximab had significantly poorer drug adherence when compared to all the other bDMARDs (p<0.01). <h3>Conclusions</h3> At 6 months9 follow-up a “poor” remission rate group (abatacept, certolizumab and infliximab), and a “good” remission rate group (adalimumab, etanercept, golimumab and tocilizumab), with rituximab in between, were found in patients with RA treated with biologics in monotherapy in routine care. <h3>References</h3> Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008;66(2):77-85. Jørgensen T.S. et al.The Prevalence of Biological Monotherapy among Rheumatoid Arthritis Patients (RA) in Denmark: Results from the Danish Nationwide DANBIO Registry. ACR congress 2013, poster no. 1478 <h3>Acknowledgements</h3> This study was supported by the Oak Foundation and Roche Denmark. <h3>Disclosure of Interest</h3> T. Jørgensen: None declared, L. Kristensen Consultant for: AbbVie, BMS, MSD and Pfizer, R. Christensen: None declared, H. Bliddal Grant/research support: Abbvie, Roche, Pfizer, and NOVO, Consultant for: Roche, Pfizer and BMS, T. Lorenzen Consultant for: Advisory Board member Roche and Pfizer, M. Hansen Consultant for: AbbVie and Roche, M. Østergaard Grant/research support: Abbott, Bristol- Myers Squibb, Centocor, GlaxoSmithKline, Janssen, Merck, Mundipharma, Novo Nordisk, Pfizer, Schering-Plough, Roche UCB, and Wyeth, Consultant for: Abbott, Bristol- Myers Squibb, Centocor, GlaxoSmithKline, Janssen, Merck, Mundipharma, Novo Nordisk, Pfizer, Schering-Plough, Roche UCB, and Wyeth, J. Jensen: None declared, L. Zanjani: None declared, T. Laursen: None declared, S. Butt: None declared, M. Dam: None declared, H. Lindegaard Consultant for: Lilly, MSD, Nordpharma and Roche, J. Espesen: None declared, O. Hendricks: None declared, P. Kumar: None declared, A. Kincses: None declared, L. Larsen: None declared, M. Andersen: None declared, E. Næser: None declared, D. Jensen: None declared, J. Grydehøj: None declared, B. Unger: None declared, N. Dufour: None declared, V. Sørensen: None declared, S. Vildhøj: None declared, I. Hansen Consultant for: Roche, Pfizer og MSD, J. Raun: None declared, N. Krogh: None declared, M. Hetland Grant/research support: Pfizer, ROche og MSD <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3651" @default.
• W2324862852 created "2016-06-24" @default.
• W2324862852 creator A5001732092 @default.
• W2324862852 creator A5004910716 @default.
• W2324862852 creator A5012288303 @default.
• W2324862852 creator A5012444517 @default.
• W2324862852 creator A5015244702 @default.
• W2324862852 creator A5016697871 @default.
• W2324862852 creator A5019342454 @default.
• W2324862852 creator A5019482399 @default.
• W2324862852 creator A5019510452 @default.
• W2324862852 creator A5021720790 @default.
• W2324862852 creator A5030452947 @default.
• W2324862852 creator A5039812289 @default.
• W2324862852 creator A5039888507 @default.
• W2324862852 creator A5041342023 @default.
• W2324862852 creator A5041719245 @default.
• W2324862852 creator A5045803373 @default.
• W2324862852 creator A5048319914 @default.
• W2324862852 creator A5050984585 @default.
• W2324862852 creator A5056156572 @default.
• W2324862852 creator A5063586848 @default.
• W2324862852 creator A5064151494 @default.
• W2324862852 creator A5064779058 @default.
• W2324862852 creator A5065094073 @default.
• W2324862852 creator A5069742158 @default.
• W2324862852 creator A5072664936 @default.
• W2324862852 creator A5081639324 @default.
• W2324862852 creator A5083175921 @default.
• W2324862852 creator A5083801035 @default.
• W2324862852 creator A5089333778 @default.
• W2324862852 creator A5089429496 @default.
• W2324862852 date "2014-06-01" @default.
• W2324862852 modified "2023-10-14" @default.
• W2324862852 title "SAT0065 Effectiveness and Drug Adherence of Biologic Monotherapy in Danish Rheumatoid Arthritis Patients: A Cohort Study of Clinical Practice in the Danbio Registry" @default.
• W2324862852 doi "https://doi.org/10.1136/annrheumdis-2014-eular.3651" @default.
• W2324862852 hasPublicationYear "2014" @default.
• W2324862852 type Work @default.
• W2324862852 sameAs 2324862852 @default.
• W2324862852 citedByCount "0" @default.
• W2324862852 crossrefType "journal-article" @default.
• W2324862852 hasAuthorship W2324862852A5001732092 @default.
• W2324862852 hasAuthorship W2324862852A5004910716 @default.
• W2324862852 hasAuthorship W2324862852A5012288303 @default.
• W2324862852 hasAuthorship W2324862852A5012444517 @default.
• W2324862852 hasAuthorship W2324862852A5015244702 @default.
• W2324862852 hasAuthorship W2324862852A5016697871 @default.
• W2324862852 hasAuthorship W2324862852A5019342454 @default.
• W2324862852 hasAuthorship W2324862852A5019482399 @default.
• W2324862852 hasAuthorship W2324862852A5019510452 @default.
• W2324862852 hasAuthorship W2324862852A5021720790 @default.
• W2324862852 hasAuthorship W2324862852A5030452947 @default.
• W2324862852 hasAuthorship W2324862852A5039812289 @default.
• W2324862852 hasAuthorship W2324862852A5039888507 @default.
• W2324862852 hasAuthorship W2324862852A5041342023 @default.
• W2324862852 hasAuthorship W2324862852A5041719245 @default.
• W2324862852 hasAuthorship W2324862852A5045803373 @default.
• W2324862852 hasAuthorship W2324862852A5048319914 @default.
• W2324862852 hasAuthorship W2324862852A5050984585 @default.
• W2324862852 hasAuthorship W2324862852A5056156572 @default.
• W2324862852 hasAuthorship W2324862852A5063586848 @default.
• W2324862852 hasAuthorship W2324862852A5064151494 @default.
• W2324862852 hasAuthorship W2324862852A5064779058 @default.
• W2324862852 hasAuthorship W2324862852A5065094073 @default.
• W2324862852 hasAuthorship W2324862852A5069742158 @default.
• W2324862852 hasAuthorship W2324862852A5072664936 @default.
• W2324862852 hasAuthorship W2324862852A5081639324 @default.
• W2324862852 hasAuthorship W2324862852A5083175921 @default.
• W2324862852 hasAuthorship W2324862852A5083801035 @default.
• W2324862852 hasAuthorship W2324862852A5089333778 @default.
• W2324862852 hasAuthorship W2324862852A5089429496 @default.
• W2324862852 hasConcept C126322002 @default.
• W2324862852 hasConcept C1862650 @default.
• W2324862852 hasConcept C198451711 @default.
• W2324862852 hasConcept C2776999253 @default.
• W2324862852 hasConcept C2777138892 @default.
• W2324862852 hasConcept C2777178219 @default.
• W2324862852 hasConcept C2777226972 @default.
• W2324862852 hasConcept C2777575956 @default.
• W2324862852 hasConcept C2779134260 @default.
• W2324862852 hasConcept C2779338263 @default.
• W2324862852 hasConcept C2779384505 @default.
• W2324862852 hasConcept C2779605438 @default.
• W2324862852 hasConcept C2779722408 @default.
• W2324862852 hasConcept C2780132546 @default.
• W2324862852 hasConcept C2780653079 @default.
• W2324862852 hasConcept C2781059491 @default.
• W2324862852 hasConcept C2781290027 @default.
• W2324862852 hasConcept C71924100 @default.
• W2324862852 hasConcept C72563966 @default.
• W2324862852 hasConceptScore W2324862852C126322002 @default.
• W2324862852 hasConceptScore W2324862852C1862650 @default.
• W2324862852 hasConceptScore W2324862852C198451711 @default.
• W2324862852 hasConceptScore W2324862852C2776999253 @default.
• W2324862852 hasConceptScore W2324862852C2777138892 @default.
• W2324862852 hasConceptScore W2324862852C2777178219 @default.
• W2324862852 hasConceptScore W2324862852C2777226972 @default.
• W2324862852 hasConceptScore W2324862852C2777575956 @default.

• next